Adipose tissue is not only a storage organ of excessive energy but is also an endocrine organ secreting many bioactive substances, namely adipocytokines. Adiponectin (Ad) is an adipose-derived, collagen-like protein that has antiartherogenic, antidiabetic, and anti-inflammatory functions \[[@B1]\]. Therefore, Ad plays an important role in the development of obesity-related disorders, such as diabetes mellitus, hypertension, dyslipidemia, and metabolic syndrome. Several studies have reported the association of hypoadiponectinemia and an increased risk of type 2 diabetes mellitus (T2DM) \[[@B1], [@B4]\]. We reported that a 3% to 5% reduction in waist circumference (WC) in nondiabetic Japanese men with abdominal obesity can reduce the risk of development of T2DM \[[@B9]\] and found that baseline serum Ad concentration is a significant factor in the onset of T2DM based on a stepwise backward selection procedure. The result highlighted the strong negative relationship between Ad levels and the development of T2DM. Increases in Ad levels were also reported to correlate significantly with a reduction in the rate of progression to T2DM \[[@B10]\].

It is not clear whether the change in Ad level can alleviate the risk of T2DM in subjects with low Ad levels who are presumed to be at a higher risk than those with high Ad levels. Moreover, the critical percent change of increase in serum Ad or the critical cutoff value of Ad levels to reduce the risk of T2DM remains unknown.

The present large-scale longitudinal study of Japanese men was designed to determine the effect of baseline Ad level on the risk of T2DM and whether the changes in Ad in subjects with low baseline serum Ad levels who are at a high risk of developing T2DM can prevent the onset of T2DM. The study also investigated whether the percent change in Ad (%*Δ*Ad) or the absolute level of Ad is important in reducing the risk of T2DM.

1. Materials and Methods {#s7}
========================

A. Subjects {#s8}
-----------

We retrospectively examined 16,395 men who underwent health checkups at the Physical Check up Center, Sumitomo Hospital, between April 2007 and May 2015, as reported previously \[[@B9]\]. The health checkup program for Japanese citizens is designed to detect diseases or risk factors at early stages. Participants often undergo the checkups spontaneously, and none had any serious diseases. The eligibility criteria for enrolment in the current study included male subjects who had undergone at least two checkup examinations between April 2007 and May 2015, with fasting plasma glucose (FPG) \<126 mg/dL, hemoglobin A1c (HbA1c) \<6.5% (48 mmol/mol), and 2-hour plasma glucose (PG) on 75 g of oral glucose tolerance test (OGTT) of \<200 mg/dL, if available, at baseline. FPG ≥126 mg/dL or 2-hour PG on OGTT ≥200 mg/dL was used to diagnose T2DM according to the criteria for the diagnosis of T2DM in Japan. Based on the clinical data, participants who were at high risk for the development of T2DM in association with visceral fat accumulation were advised to improve their dietary habits and engage in adequate aerobic exercise to avoid the potential development of T2DM. Subjects who used glucose-lowering agents or who had regular visits to the hospital or family physician for T2DM were excluded from the study. We also excluded participants with missing serum Ad levels of baseline or endpoint. Using these criteria, 7052 men were included in the current study.

The study was approved by the human ethics committees of Sumitomo Hospital and Osaka University and conducted according to the principles of the Declaration of Helsinki. Informed consent to provide medical information and blood samples was obtained before the checkup examinations from all participants, and all subjects had the right to refuse the use of their results.

B. Clinical and Laboratory Assessment {#s9}
-------------------------------------

Clinical and laboratory data were assessed as described in detail previously \[[@B9]\]. Briefly, physical examination to determine height, body weight (BW), WC, and blood pressure was conducted after overnight fasting. WC was measured at the level of the umbilicus based on the recommendation of the Japan Society for the Study of Obesity \[[@B11]\]. Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters. Information about the use of medications, family history of diabetes, and regular visits to the hospital or family physician was obtained by questionnaires. Blood samples were obtained for measurement of FPG, fasting serum immunoreactive insulin (F-IRI), HbA1c, lipid profile, uric acid (UA), and creatinine (Cr). The reported value for HbA1c (%) represented the National Glycohemoglobin Standardization Program (NGSP). The formula used for conversion of HbA1c (Japan Diabetes Society) to HbA1c (NGSP) was as follows: HbA1c (NGSP) (%) = 1.02 × HbA1c (Japan Diabetes Society) (%) + 0.25% \[[@B12], [@B13]\]. The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as F-IRI (μU/mL) × FPG (mg/dL)/405. Serum total Ad level was measured by the latex particle-enhanced turbidimetric immunoassay (Human Adiponectin Latex Kit; Otsuka Pharmaceutical Co., Tokyo, Japan). The within-run and total coefficient of variation of this measurement were 0.8% to 1.9% and 1.1% to 2.0%, respectively, and the results correlated highly with those obtained by enzyme-linked immunosorbent assay (*r* = 0.99) \[[@B14]\]. %ΔAd was estimated at the end of the observation period and was calculated as follows: (Ad at endpoint − Ad at baseline)/Ad at baseline. Changes in BW (%*Δ*BW) and WC (%*Δ*WC) were calculated in a manner similar to that applied for %*Δ*Ad calculation.

C. Endpoints and Categorization {#s10}
-------------------------------

Each participant was followed from the first visit to Physical Check up Center in our hospital to the diagnosis of T2DM or the last visit for checkup by May 2015. In this study, T2DM was set at HbA1c ≥6.5% (48 mmol/mol), FPG ≥126 mg/dL, or 2-hour PG on OGTT ≥200 mg/dL if conducted. The mean follow-up period was 3.9 ± 2.2 years (range, 0.4 to 8.1 years).

We compared the cumulative incidence rates of T2DM according to baseline serum Ad levels to identify the group of subjects with baseline Ad levels associated with the highest risk of developing T2DM. We divided the participants into quartile groups according to the baseline level of serum Ad.

We selected the group with the lowest Ad (baseline serum Ad ≤5.2 μg/mL) as the high-risk group and examined whether the increase in serum Ad level could alleviate the risk of T2DM using %*Δ*Ad and endpoint serum Ad level. Thus, the lowest baseline Ad quartile (≤5.2 μg/mL) was subdivided into four subgroups according to %*Δ*Ad: the %*Δ*Ad-decreased group and the tertile of the %*Δ*Ad-increased groups. A multivariate analysis was applied to investigate whether %*Δ*Ad is an independent factor that can influence the development of T2DM.

We also assessed the effect of endpoint serum Ad level. Subjects with the lowest baseline serum Ad levels (≤5.2 μg/mL) were divided into two subgroups according to the serum Ad level at endpoint: endpoint Ad \>5.2 and ≤5.2 μg/mL.

D. Statistical Analysis {#s11}
-----------------------

Data are presented as mean ± standard deviation or number/percentage of participants. First, the cumulative incidence rates of T2DM of each baseline Ad group were compared by using the Kaplan-Meier product limit method and the log-rank test. Second, the variables of %*Δ*Ad subgroups were compared using analysis of variance. We analyzed *post hoc* multiple comparisons by Tukey test. We compared the cumulative incidence rates of T2DM among the four subgroups according to %*Δ*Ad using the Kaplan-Meier product limit method and log-rank test. The cumulative incidence rate for each %*Δ*Ad-increased tertile was compared with that of the %*Δ*Ad-decreased group. Cox proportional hazard analysis was used to estimate the multivariable adjusted hazard ratio (HR) and 95% confidence interval (CI) of the %*Δ*Ad subgroups. Factors associated with the development of T2DM were evaluated using multivariate Cox proportional hazards regression models. We selected the covariates by the Pearson product moment correlation coefficient procedure and excluded factors that were significantly associated with the change in Ad level. The multivariable models included the covariates of BMI, HbA1c, F-IRI, triglyceride, Cr, UA, and %*Δ*Ad subgroups. We then used the stepwise backward selection procedure to identify those variables that independently and significantly influenced the development of T2DM based on the *P* value.

Variables of two endpoint Ad subgroups (endpoint Ad \>5.2 and ≤5.2 μg/mL) were compared using the Mann-Whitney *U* test. We compared the cumulative incidence rates of T2DM between the two endpoint Ad subgroups using the Kaplan-Meier product limit method and log-rank test. The cumulative incidence rate was compared between the two endpoint Ad subgroups. Cox proportional hazard analysis was also used to estimate the multivariable adjusted HR and 95% CI of the endpoint Ad subgroups. The covariates were selected by the Pearson product moment correlation coefficient procedure, and factors that were significantly associated with the endpoint Ad level were excluded. The multivariable models included the covariates of BMI, HbA1c, total cholesterol, Cr, UA, and endpoint Ad subgroups. We then used the stepwise backward selection procedure to identify variables that independently and significantly influenced the development of T2DM based on the *P* value.

We performed the Kruskal-Wallis test and confirmed that there were no significant differences in the time periods from the previous visits to endpoints between each group. All statistical analyses were performed using SPSS software version 23 for Windows (SPSS Inc., Chicago, IL). A *P* value \<0.05 was considered statistically significant.

2. Results {#s12}
==========

A. Cumulative Incidence Rates of T2DM According to Baseline Serum Ad Level {#s13}
--------------------------------------------------------------------------

The cumulative incidence rate of T2DM was significantly higher in the lowest baseline serum Ad quartile (≤5.2 μg/mL) than in the highest quartile (≥9.6 μg/mL) and the second highest (7.1 to 9.5 μg/mL) baseline quartile ([Fig. 1](#F1){ref-type="fig"}).

![Kaplan-Meier curves of the proportion of diabetes-free participants stratified according to serum Ad level at baseline. The cumulative incidence rates of T2DM in individuals of the baseline Ad quartiles (highest, ≥9.6 μg/mL; second highest, 7.1 to 9.5 μg/mL; third highest, 5.3 to 7.0 μg/mL; lowest, ≤5.2 μg/mL) were 2.7%, 3.6%, 5.1%, and 6.7%, respectively. The cumulative incidence rate of subjects of the lowest Ad quartile was significantly higher than that of subjects of the highest and second highest Ad quartiles (*P* \< 0.001 and *P* \< 0.001, respectively).](js.2018-00033f1){#F1}

B. Cumulative Incidence Rates of T2DM According to Change in Ad of the Lowest Baseline Ad Group {#s14}
-----------------------------------------------------------------------------------------------

The lowest baseline Ad quartile (≤5.2 μg/mL) was subdivided into four subgroups according to %*Δ*Ad. The baseline clinical characteristics of the patients of the four subgroups are summarized in [Table 1](#T1){ref-type="table"}. There were no significant differences among the subgroups in BMI, WC, BW, FPG, HbA1c, UA, lipid profile, F-IRI, HOMA-IR, and the proportion of participants with family history of diabetes. In each subgroup, %*Δ*BW and %*Δ*WC were significantly inversely associated with %*Δ*Ad. Furthermore, there were significant differences in age of subjects of the four subgroups but no significant differences by Turkey test between the %*Δ*Ad-increased subgroups and the %*Δ*Ad-decreased subgroup. We also analyzed the data after adjustment for age at baseline, and similar results were obtained for the cumulative incidence rate and for the proportion of diabetes-free participants (data not shown). The results also showed significant differences in baseline serum Ad levels among the %*Δ*Ad subgroups. However, there was no specific increase or decrease tendency in those parameters in each subgroup. [Figure 2A](#F2){ref-type="fig"} shows the cumulative incidence rate and the proportion of diabetes-free subjects for each subgroup. The cumulative incidence rates of the %*Δ*Ad-increased subgroups (largest, ≥21.5%; second largest, 9.3% to 21.4%; third largest, ≤9.1%) and of the %*Δ*Ad-decreased subgroup were 2.9%, 5.5%, 7.0%, and 9.9%, respectively. The cumulative incidence rates were significantly lower in the largest (≥21.5%) and the second largest (9.3% to 21.4%) %*Δ*Ad-increased subgroups than in the %*Δ*Ad-decreased subgroup (*P* \< 0.001 and *P* = 0.005, respectively). There was no significant difference in the cumulative incidence rate between the third largest %*Δ*Ad-increased subgroup (≤9.1%) and the %*Δ*Ad-decreased subgroup.

###### 

Baseline Clinical Characteristics of Subjects of the %*Δ*Ad Subgroups and Endpoint Ad Subgroups

                                      \%*Δ*Ad Subgroups   Endpoint Ad Subgroups                                                                                                                                                                                         
  ----------------------------------- ------------------- ----------------------- ------------------------------------------------ ----------------------------------------------- ---------------------------------------------- --------- ------------- ------------- ---------
  n                                   1698                544                     382                                              384                                             388                                                      404           1294          
  Age, y                              49 ± 10             48 ± 10                 50 ± 10                                          50 ± 10                                         49 ± 10                                        0.037     51 ± 10       49 ± 10       0.002
  BMI, kg/m^2^                        24.6 ± 2.9          24.6 ± 2.8              24.8 ± 3.0                                       24.7 ± 3.0                                      24.5 ± 2.9                                     0.693     24.5 ± 3.0    24.7 ± 2.9    0.213
  BW, kg                              72.0 ± 10.3         71.7 ± 9.4              72.7 ± 11.2                                      72.4 ± 10.6                                     71.5 ± 10.2                                    0.710     72.1 ± 11.1   72.0 ± 10.0   0.803
  WC, cm                              87.9 ± 7.7          87.6 ± 7.5              88.7 ± 8.2                                       88.1 ± 7.6                                      87.5 ± 7.3                                     0.258     88.0 ± 8.0    87.9 ± 7.6    0.838
  SBP, mm Hg                          126 ± 14            125 ± 15                127 ± 15                                         125 ± 13                                        125 ± 13                                       0.152     127 ± 14      126 ± 14      0.055
  DBP, mm Hg                          79 ± 9              79 ± 10                 80 ± 10                                          79 ± 10                                         79 ± 9                                         0.153     80 ± 10       79 ± 9        0.013
  Total cholesterol, mg/dL            213 ± 33            216 ± 34                210 ± 33                                         210 ± 32                                        212 ± 32                                       0.074     209 ± 31      214 ± 33      0.041
  HDL cholesterol, mg/dL              53 ± 12             54 ± 12                 53 ± 13                                          54 ± 12                                         53 ± 10                                        0.440     54 ± 12       53 ± 12       0.722
  LDL cholesterol, mg/dL              132 ± 31            134 ± 31                129 ± 30                                         131 ± 30                                        133 ± 31                                       0.185     131 ± 30      133 ± 31      0.486
  TG, mg/dL                           176 ± 135           184 ± 135               180 ± 158                                        169 ± 129                                       169 ± 114                                      0.100     160 ± 106     182 ± 143     0.001
  UA, mg/dL                           6.5 ± 1.2           6.5 ± 1.2               6.5 ± 1.2                                        6.4 ± 1.2                                       6.5 ± 1.2                                      0.339     6.4 ± 1.1     6.5 ± 1.2     0.222
  FPG, mg/dL                          97 ± 9              97 ± 9                  97 ± 9                                           97 ± 10                                         97 ± 9                                         0.955     97 ± 9        97 ± 10       0.892
  HbA1c, %                            5.2 ± 0.4           5.3 ± 0.4               5.2 ± 0.4                                        5.3 ± 0.4                                       5.3 ± 0.4                                      0.451     5.2 ± 0.4     5.3 ± 0.4     0.056
  Cr, mg/dL                           0.83 ± 0.13         0.83 ± 0.13             0.84 ± 0.16                                      0.84 ± 0.13                                     0.83 ± 0.12                                    0.476     0.83 ± 0.13   0.83 ± 0.13   0.750
  HOMA-IR                             1.9 ± 1.1           1.9 ± 1.1               2.0 ± 1.2                                        1.9 ± 1.2                                       1.8 ± 1.0                                      0.521     1.8 ± 1.0     2.0 ± 1.1     0.003
  F-IRI. μU/mL                        7.9 ± 4.4           8.0 ± 4.1               8.1 ± 4.9                                        7.9 ± 4.5                                       7.6 ± 4.0                                      0.370     7.4 ± 4.2     8.1 ± 4.4     0.003
  Baseline Ad, μg/mL                  4.1 ± 0.8           4.2 ± 0.8               4.1 ± 0.8[*^b^*](#t1n2){ref-type="table-fn"}     4.0 ± 0.8[*^b^*](#t1n2){ref-type="table-fn"}    4.2 ± 0.7                                      \<0.001   4.7 ± 0.4     4.0 ± 0.8     \<0.001
  Ad at endpoint, μg/mL               4.5 ± 1.2           3.8 ± 0.8               5.7 ± 1.4[*^b^*](#t1n2){ref-type="table-fn"}     4.6 ± 0.9[*^b^*](#t1n2){ref-type="table-fn"}    4.4 ± 0.8[*^b^*](#t1n2){ref-type="table-fn"}   \<0.001   6.2 ± 0.9     4.0 ± 0.8     \<0.001
  \%*Δ*Ad, %                          9.7 ± 22.4          −11.4 ± 8.0             40.4 ± 22.1[*^b^*](#t1n2){ref-type="table-fn"}   15.1 ± 3.5[*^b^*](#t1n2){ref-type="table-fn"}   3.8 ± 3.0[*^b^*](#t1n2){ref-type="table-fn"}   \<0.001   31.9 ± 25.6   2.8 ± 16.0    \<0.001
  \%*Δ*BW, %                          −0.5 ± 4.8          1.5 ± 4.2               −3.8 ± 5.6[*^b^*](#t1n2){ref-type="table-fn"}    −0.9 ± 4.2[*^b^*](#t1n2){ref-type="table-fn"}   0.4 ± 3.7[*^b^*](#t1n2){ref-type="table-fn"}   \<0.001   −2.8 ± 5.7    0.2 ± 4.3     \<0.001
  \%*Δ*BMI, %                         −0.2 ± 4.8          1.6 ± 4.2               −3.4 ± 5.6[*^b^*](#t1n2){ref-type="table-fn"}    −0.6 ± 4.2[*^b^*](#t1n2){ref-type="table-fn"}   0.6 ± 3.7[*^b^*](#t1n2){ref-type="table-fn"}   \<0.001   −2.4 ± 5.6    0.4 ± 4.3     \<0.001
  \%*Δ*WC, %                          −0.4 ± 4.7          1.2 ± 4.2               −3.1 ± 5.3[*^b^*](#t1n2){ref-type="table-fn"}    −0.7 ± 4.3[*^b^*](#t1n2){ref-type="table-fn"}   0.4 ± 4.0[*^b^*](#t1n2){ref-type="table-fn"}   \<0.001   −2.3 ± 5.4    0.2 ± 4.3     \<0.001
  Family history of diabetes, n (%)   412 (24.2)          143 (26.3)              96 (25.1)                                        74 (19.3)                                       99 (25.5)                                      0.075     85(21.0)      327 (25.3)    0.083

Abbreviations: ANOVA, analysis of variance; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure; TG, triglyceride; %*Δ*Ad, percent change in serum adiponectin; %*Δ*BW, percent change in body weight; %*Δ*WC, percent change in waist circumference.

Data are mean **±** standard deviation or number of subjects.

*P* \< 0.05 compared with the decreased group by the Mann-Whitney *U* test.

*P* \< 0.05 compared with the decreased group by *post hoc* multiple comparisons (Turkey test).

![Kaplan-Meier curves of the proportion of diabetes-free participants of the lowest baseline Ad group. (A) Kaplan-Meier curves of the proportion of diabetes-free participants of the %*Δ*Ad-increased subgroups of the lowest baseline Ad group. The cumulative incidence rates of T2DM for subjects of the %*Δ*Ad-increased subgroups (largest, ≥21.5%; second largest, 9.3% to 21.4%; third largest, ≤9.1%) and the %*Δ*Ad-decreased subgroup were 2.9%, 5.5%, 7.0%, and 9.9%, respectively. The cumulative incidence rate was significantly lower in subjects of the largest (≥21.5%) and second largest (9.3% to 21.4%) %*Δ*Ad-increased subgroups than in the %*Δ*Ad-decreased subgroup (*P* \< 0.001 and *P* = 0.005, respectively). (B) Kaplan-Meier curves of the proportion of diabetes-free participants of the endpoint Ad subgroups of the lowest baseline Ad group. The cumulative incidence rates of T2DM for subjects of the endpoint Ad subgroups (endpoint Ad \>5.2 and ≤5.2 μg/mL) were 3.0% and 7.8%, respectively. The cumulative incidence rate was significantly lower in the endpoint Ad \>5.2 μg/mL subgroup than in the endpoint Ad ≤5.2 μg/mL subgroup (*P* \< 0.001).](js.2018-00033f2){#F2}

[Table 2](#T2){ref-type="table"} shows the results of multivariate Cox proportional hazards regression analyses. Baseline HbA1c, F-IRI, UA, Cr, and %*Δ*Ad were identified as significant factors in the development of T2DM. The results of stepwise backward selection procedure are also shown in [Table 2](#T2){ref-type="table"}. Baseline HbA1c, F-IRI, UA, Cr, and %*Δ*Ad were the most significant factors.

###### 

Hazard Ratios for the Development of T2DM (%*Δ*Ad)

                                            HR       95% CI           *P* Value
  ----------------------------------------- -------- ---------------- -----------
  BMI                                       1.057    0.907--1.132     NS
  HbA1c                                     19.126   11.799--31.002   \<0.001
  F-IRI                                     1.051    1.009--1.095     0.018
  TG                                        1.000    0.999--1.002     NS
  Cr                                        0.424    0.119--1.503     0.014
  UA                                        0.833    0.717--0.975     0.022
  \%*Δ*Ad                                                             
   Largest subgroup (≥21.5%)                0.196    0.102--0.377     \<0.001
   Second largest subgroup (9.3%--21.4%)    0.381    0.225--0.645     \<0.001
   Third largest subgroup (≤9.1%)           0.753    0.472--1.200     NS
  Stepwise backward selection procedure                               
   HbA1c                                    19.977   12.320--32.392   \<0.001
   F-IRI                                    1.071    1.036--1.107     \<0.001
   Cr                                       0.145    0.029--0.716     0.010
   UA                                       0.852    0.731--0.992     0.039
   %*Δ*Ad                                                             
    Largest subgroup (≥21.5%)               0.201    0.105--0.386     \<0.001
    Second largest subgroup (9.3%--21.4%)   0.381    0.226--0.642     \<0.001
    Third largest subgroup (≤9.1%)          0.761    0.478--1.211     0.249

Abbreviations: NS, not significant; TG, triglyceride; %*Δ*Ad, percent change in serum adiponectin level.

C. Cumulative Incidence Rates of T2DM According to Ad at Endpoint of the Lowest Baseline Ad Group {#s15}
-------------------------------------------------------------------------------------------------

The group of subjects with the lowest baseline Ad (≤5.2 μg/mL) was divided into two subgroups according to serum Ad level at endpoint: endpoint Ad \>5.2 and ≤5.2 μg/mL. The baseline clinical characteristics of subjects of the two subgroups are summarized in [Table 1](#T1){ref-type="table"}. For each endpoint Ad subgroup, there were no significant differences between the subjects in BMI, WC, BW, FPG, HbA1c, UA, Cr, and the proportion of participants with family history of diabetes. There were significant differences in age, %*Δ*BW, and %*Δ*WC of each endpoint Ad subgroup. Similar results of cumulative incidence rate and proportion of diabetes-free participants were obtained after adjustment for age at baseline (data not shown). We also found significant differences in baseline Ad, HOMA-IR, and F-IRI of endpoint Ad subgroups. [Figure 2B](#F2){ref-type="fig"} shows the cumulative incidence rate and proportion of diabetes-free subjects for the two endpoint Ad subgroups. The cumulative incidence rates of the endpoint Ad subgroups were 3.0% and 7.8% for the endpoint adiponectin \>5.2 μg/mL and endpoint adiponectin ≤5.2 μg/mL groups, respectively. The cumulative incidence rate was significantly lower in the former than in the latter subgroup (*P* \< 0.001). We also performed multivariate Cox proportional hazards regression analysis and the stepwise backward selection procedure in a manner similar to that applied for %*Δ*Ad to evaluate the significance of Ad at endpoint. Ad at endpoint was a significant factor that reduced the risk of the development of T2DM ([Table 3](#T3){ref-type="table"}).

###### 

Hazard Ratios for the Development of T2DM (Endpoint Ad)

                                          HR       95% CI           *P* Value
  --------------------------------------- -------- ---------------- -----------
  BMI                                     1.073    1.014--1.136     0.015
  HbA1c                                   19.907   12.311--32.189   \<0.001
  Total cholesterol                       0.998    0.993--1.004     NS
  Cr                                      0.105    0.022--0.512     0.005
  UA                                      0.909    0.780--1.059     NS
  Endpoint Ad \>5.2 μg/mL subgroup        0.274    0.149--0.503     \<0.001
  Stepwise backward selection procedure                             
   HbA1c                                  19.662   12.195--31.702   \<0.001
   BMI                                    1.062    1.007--1.121     0.026
   Cr                                     0.087    0.018--0.410     0.002
   Endpoint Ad \>5.2 μg/mL subgroup       0.275    0.150--0.504     \<0.001

Abbreviation: NS, not significant.

D. Results After Adjusting for the Change in BMI {#s16}
------------------------------------------------

Linear regression model analysis revealed that %*Δ*Ad and %*Δ*BMI had significant correlation (*P* \< 0.001). We then performed Cox proportional hazard analysis and stepwise backward selection procedure, which are similar to %*Δ*Ad, to assess the influence of %*Δ*BMI. The multivariable models included the covariates of %*Δ*BMI, HbA1c, Cr, and LDL-cholesterol. %*Δ*BMI was the significant factor (HR, 1.086; 95% CI, 1.048 to 1.126; *P* \< 0.001). Therefore, we selected the subjects from the group with the lowest Ad (baseline serum Ad ≤5.2 μg/mL) whose %*Δ*BMI increased and adjusted the mean of %*Δ*BMI. The cumulative incidence rate was significantly lower in the %*Δ*Ad-increased subgroup (≥11.4%) than in the %*Δ*Ad-decreased subgroup (*P* = 0.002). Moreover, the cumulative incidence rate was significantly lower in the endpoint Ad \>5.2 μg/mL subgroup than in the endpoint Ad ≤5.2 μg/mL subgroup (*P* = 0.008). The results were consistent after adjusting for the change in BMI.

3. Discussion {#s17}
=============

Results from this large-scale longitudinal study suggest that an increase in Ad levels could reduce the risk of T2DM in Japanese men with low baseline Ad levels. Moreover, this study shows that an increase of Ad levels of at least \~10% or \>5.2 μg/mL in Japanese men with low Ad levels is potentially beneficial to prevent the onset of T2DM.

Our study has several important features. This study examined the longitudinal effect of increase in Ad in subjects with low Ad levels on the development of T2DM. Serum Ad concentrations correlated strongly with insulin sensitivity, suggesting that hypoadiponectinemia is associated with insulin resistance \[[@B15]\]. In our study, the risk of development of T2DM was significantly higher in subjects with baseline serum Ad of ≤5.2 μg/mL compared with those with ≥7.1 μg/mL. This result is consistent with previous studies that reported the association between hypoadiponectinemia and increased risk of T2DM \[[@B1], [@B4]\]. Furthermore, a meta-analysis of past reports showed the consistency of the association across studies with diverse populations \[[@B7]\]. Previous studies indicated that serum Ad levels in Japanese subjects were significantly inversely associated with the incidence of T2DM, with odds ratios of 0.79 (Ad level of 5.2 to 6.8 μg/mL), 0.60 (6.9 to 9.5 μg/mL), and 0.40 (≥9.6 μg/mL) compared with the group with an Ad level of \<5.2 μg/mL \[[@B16]\]. These baseline Ad quartiles are similar to those used in our study, although the past studies included both male and female subjects. Although it has been reported that low serum Ad level is an important risk factor for T2DM, our study focused on changes in serum Ad in subjects with low baseline Ad. A healthier dietary pattern was confirmed to be positively and independently associated with total and high-molecular-weight plasma Ad concentrations \[[@B17]\]. Another study showed that a 1 μg/mL increase in serum Ad level was associated with a 16% reduction in the rate of progression to T2DM in the lifestyle intervention group \[[@B10]\]. However, there is little information on the effect of change in serum Ad level in subjects with low Ad levels on the development of T2DM. The current study showed that an increase in serum Ad levels could prevent the onset of T2DM in Japanese men with low baseline Ad levels who are at high risk of developing T2DM.

The current study also suggested that the risk of development of T2DM can be reduced by a ≥10% increase in serum Ad or an increase in Ad level of \>5.2 μg/mL in Japanese men with low baseline serum Ad level. Our study suggested that visceral fat reduction aiming at increasing Ad levels might be useful in preventing the onset of T2DM. The changes in BW and WC were found to be significantly inversely associated with the change in serum Ad levels. Accumulation of visceral fat leads to the development of T2DM, dyslipidemia, hypertension, and arteriosclerosis. The prevalence of T2DM is known to be high in subjects with visceral fat area of ≥100 cm^2^ \[[@B18]\]. Another study showed that an increase in WC is significantly associated with a 9-year incidence of T2DM, with a standardized odds ratio of 1.79 (95% CI, 1.45 to 2.21) \[[@B19]\]. Therefore, a reduction of visceral fat is expected to improve or prevent metabolic disorders, including T2DM. Several studies have reported that a decrease in visceral fat improved glucose tolerance \[[@B20]\]. We have also demonstrated that WC reduction, which parallels visceral fat reduction, of at least \~3% in young (\<55 years) men and \~5% in elderly (≥55 years) nondiabetic Japanese men with abdominal obesity can reduce the chance of developing T2DM \[[@B9]\]. It is widely known that hypoadiponectinemia induced by visceral fat accumulation is closely associated with T2DM \[[@B1], [@B4]\]. In our previous study, we also found that baseline serum Ad concentration is an important risk factor for the onset of T2DM based on results of a stepwise backward selection procedure, suggesting a strong relationship between Ad and visceral fat accumulation \[[@B9]\]. Another study concluded that serum Ad levels correlate negatively with visceral fat accumulation, as measured by CT scan at the level of umbilicus \[[@B23]\]. In this regard, the change in Ad noted in the current study may be due to a change in visceral fat accumulation, which corresponds to WC. Based our results, the change in serum Ad level can be a useful marker of risk of development of T2DM through a change in visceral fat accumulation.

However, using the stepwise backward selection procedure in our study, we demonstrated that Ad at endpoint reduced the risk of the development of T2DM. In addition, the results of cumulative incidence rates of T2DM according to Ad at endpoint of the lowest baseline Ad group were consistent after adjusting for the change in BMI. These results suggested that the level of Ad could be recognized as not only the marker of change in visceral fat accumulation but also as one of the risk factors of developing T2DM and that there would be an absolute level of Ad to reduce the risk. In other words, hypoadiponectinemia might be the risk factor of developing T2DM. The effect of hypoadiponectinemia toward developing T2DM might be independent of visceral fat accumulation. The mechanisms responsible for the antidiabetic effect of high Ad level remain unclear. Ad is known to accumulate in the heart, vascular endothelium, and skeletal muscles through interaction with T-cadherin, and this interaction is essential for Ad-mediated cardiovascular protection \[[@B24]\]. It has been reported that skeletal muscle mass is inversely associated with insulin resistance \[[@B27]\]. Similar to the cardiovascular-protective effect of the interaction of Ad and T-cadherin, its antidiabetic effect may be mediated through the interaction of Ad and T-cadherin, which is present in large concentrations in skeletal muscles. Also, it has been suggested that Ad enhances insulin sensitivity by activating insulin-receptor substrate 1--associated phosphatidylinositol 3 kinase, accelerates FFA clearance by enhancing fatty-acid transport protein 1 mRNA expression, and ameliorates TNF-*α*--mediated suppression of these parameters. Furthermore, Ad and TNF-*α* were found to induce local and reciprocal suppression in adipose tissue \[[@B28]\]. Another report showed that Ad increased phosphorylation and the activity of 5′-AMP--activated protein kinase and simultaneously increased glucose uptake in skeletal muscles and reduced the expression of molecules involved in gluconeogenesis in the liver \[[@B29]\]. Moreover, the Ad receptors AdipoR1 and AdipoR2 are thought to be downregulated in obesity-linked insulin resistance \[[@B30], [@B31]\]. A critical level of Ad might be required to produce the antidiabetic effects through the above-mentioned mechanisms. If the absolute levels of Ad that prevent T2DM could be determined, the treatment of hypoadiponectinemia might be a good therapeutic strategy to prevent T2DM.

The age at baseline of subjects of the %*Δ*Ad-increased subgroups was significantly different from that of the %*Δ*Ad-decreased subgroup, although no significant differences were found among the subgroups with respect to baseline age when we performed *post hoc* analysis with Turkey tests. We also analyzed the data after adjustment for age at baseline, and similar results of cumulative incidence rate and proportion of diabetes-free participants were obtained. Therefore, we think that it is not necessary to take the difference into consideration.

The stepwise backward selection procedure in our study showed that baseline HbA1c, F-IRI, UA, and Cr were important factors in the development of T2DM. HbA1c is used to diagnose diabetes, and it is reasonable that HbA1c is an important factor in the development of T2DM. An increase of F-IRI concentration suggests the existence of insulin resistance. It is also reasonable that F-IRI is an important factor in the development of T2DM. In addition, the amount of serum Cr depends on the amount of skeletal muscle tissue. It is suggested that higher muscle mass is associated with the reduced risk of developing T2DM. Moreover, the loss of body weight is known to cause a temporary increase in serum UA levels \[[@B32]\]. The risk of developing T2DM is suggested to be lowered by a decrease in visceral fat that is associated with increase in serum UA.

It has been reported that plasma Ad levels could be changed in statin therapy \[[@B33], [@B34]\]. We performed the same analysis after excluding the subjects who were using lipid-lowering agents at the endpoint. Similar results of cumulative incidence rate and proportion of diabetes-free participants were obtained.

Our study has several limitations. First, the inclusion of subjects who underwent health checkups may imply selection bias toward highly health-conscious people. The baseline serum Ad level or the extent of change in serum Ad might be different in other cohorts, but we think that our population is appropriate for investigating the relationship between baseline and change in serum Ad level and the development of T2DM. Second, we advised the participants regarding dietary habits and exercise, but we did not evaluate whether such dietary and exercise habits improved or not. Third, this study included only male subjects because the majority of participants who underwent health checkups were male. Therefore, the results of our study cannot be applied to women.

In summary, our study demonstrated that increases in serum Ad levels can reduce the risk T2DM in Japanese men with low baseline Ad levels. Moreover, the target level of Ad increase (at least \~10% or \>5.2 μg/mL) in Japanese men with low serum Ad levels is potentially beneficial in the prevention of T2DM.
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Ad

:   adiponectin

BMI

:   body mass index

BW

:   body weight

CI

:   confidence interval

Cr

:   creatinine

F-IRI

:   fasting serum immunoreactive insulin

FPG

:   fasting plasma glucose

HbA1c

:   hemoglobin A1c

HOMA-IR

:   homeostasis model assessment of insulin resistance

HR

:   hazard ratio

NGSP

:   National Glycohemoglobin Standardization Program

OGTT

:   oral glucose tolerance test

PG

:   plasma glucose

T2DM

:   type 2 diabetes mellitus

UA

:   uric acid

WC

:   waist circumference
